通達股份(002560.SZ):預中標7.69億元南方電網項目
格隆匯3月11日丨通達股份(002560.SZ)公佈,中國南方電網-供應鏈統一服務平台於近日在“採購公吿\公示公吿”中發佈了《南方電網公司2024年主網線路材料第二批框架招標項目中標公示》(簡稱“公示1”)、《南方電網公司2024年配網材料第二批框架招標項目中標公示》(簡稱“公示2”),公示開始時間為2025年3月10日,公示結束時間為2025年3月13日。據河南通達電纜股份有限公司測算,在上述公示中公司預中標物資總價值共計人民幣76,883.894595萬元,約佔公司2023年度營業總收入的13.80%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.